Caprion

Accelerating precision medicine™

Press Release

Abbott Laboratories And Caprion Pharmaceuticals Announce Drug Discovery Collaboration In Oncology

ABBOTT PARK, Ill., and MONTREAL, Canada, Feb. 4, 2004 - Abbott Laboratories and Caprion Pharmaceuticals Inc. have announced a research collaboration applying Caprion's quantitative proteomics platform, CellCartaTM, for the discovery of novel antibody targets and the development of therapeutics for the treatment of lung cancer.

Under the terms of the collaboration, Abbott will non-exclusively evaluate a number of drug targets for non-small-cell lung cancer previously discovered by Caprion, as well as a number of additional targets that Caprion discovers in its ongoing lung cancer program. Abbott will obtain exclusive, worldwide rights to develop and commercialize therapeutic applications for its selected targets. Caprion will retain rights to certain other targets for pursuit of internal or partnered product development efforts.

The terms of the agreement include an up-front payment to Caprion, additional payments to Caprion contingent upon successful completion of milestones by both Caprion and Abbott, and royalty payments to Caprion from future product sales by Abbott. Specific financial terms of the agreement were not disclosed.

"We are excited about the ability of Caprion's proteomics technology to identify novel cell-surface targets for the development of new antibody therapies in cancer," said Stephen W. Fesik, Ph.D., divisional vice president, Cancer Research, Abbott Laboratories. "Combined with Abbott's depth in the development of monoclonal antibody therapies, Caprion's advances in applying proteomics to lung cancer may substantially accelerate our efforts to deliver new therapies to patients who need them."

"This collaboration with Abbott, Caprion's sixth pharmaceutical proteomics partnership, helps solidify our position as the leader in proteomics-based drug discovery," said Martin LeBlanc, Caprion's EVP & Chief Operating Officer. "In concert with our recent advances in the discovery of drug targets for colon cancer as well as several programs in pharmaco-proteomics and biomarker discovery, we are proving that our distinctive proteomics approach can have a significant impact in the drug discovery process."

CellCartaTM is Caprion's proprietary proteomics approach for comprehensive and quantitative profiling of the protein complement of cells through comparisons of normal and disease conditions. In cancer, Caprion compares proteins present in purified plasma membranes isolated from normal and diseased tissues, leading to large-scale discovery and functional characterization of cell-surface protein targets and disease markers suitable for the development of targeted antibody therapies.

About Caprion Pharmaceuticals
Caprion is a leading proteomics-based drug discovery company applying CellCartaTM to discover and develop innovative products for the diagnosis and treatment of disease. Caprion has an established colorectal cancer target discovery partnership with Biogen IDEC (NASDAQ: BIIB), and ongoing pharmaco-proteomic and biomarker discovery collaborations with Wyeth (NYSE: WYE), AstraZeneca (NYSE: AZN) and Merck and Co (NYSE: MRK). Caprion has also partnered products for Mad Cow Disease and variant Creutzfeldt-Jacob Disease diagnostics, in development with IDEXX Laboratories (NASDAQ: IDXX) and Ortho-Clinical Diagnostics, a Johnson & Johnson company (NYSE:JNJ). For more on Caprion, see https://www.caprion.com.

About Abbott Laboratories
Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals and medical products, including devices and diagnostics. The company employs more than 70,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at https://www.abbott.com.

FOR MORE INFORMATION CONTACT:

Abbott Laboratories
Media
Jennifer Smoter
(847) 935-8865
- or -
Elizabeth Hoff
(847) 935-4236

Caprion Pharmaceuticals
Katherine Bonter
(514) 940-3624
- or -
Emily Poe
Noonan Russo Presence
(212) 845-4266

Investor Community
Larry Peepo
(847) 935-6722

Back to news list


Caprion

Accreditations & Certifications

CAP accreditation and CLIA certification

CAP Accredited

Headquarters

+1 514.360.3600
+1 877.776.3443
141 President Kennedy Ave., Suite SB-5658
Montreal, Quebec
CANADA

USA

Primity Bio
48383 Fremont Blvd
Suite 118
Fremont, CA 94538
Tel.: +1 858.229.2529

Serametrix
2235 Farraday Ave,Suite N,
Carlsbad, CA, 92008, USA
Tel: +1 760 652 4060

HistoGeneX
1331 W 75th St #401,
Naperville, IL 60540, USA
Tel: +1 630-473-6655
info@histogenex.com

AUSTRALIA

Serametrix Party Limited
Suite 4/54-60 Briggs Street
Camperdown, NSW, 2050
Australia
+61 2 9168 5908

EUROPE

Caprion Biosciences Inc.
+32 (0) 71 96 23 36
8 rue Adrienne Bolland
6041 Gosselies
BELGIUM

Serametrix
Unit 22, Surrey Technology Centre,
40 Occam Road,
Guildford, Surrey, UK
GU2 7YG
Tel: +44 1483 685599

Antwerp, Belgium
HistoGeneX
Sint-Bavostraat 78
2610 Antwerpen (Wilrijk)
Belgium
Tel: +32 3 50 20 500
Sample Reception: +32 3 50 20 620
Shipments: +32 3 50 20 625

CANADA LAB

201 President Kennedy Ave., Suite PK-3900
Montreal, Quebec
CANADA
+1 514.360.3600
+1 877.776.3443



Follow us

        

Contact

+1 877.776.3443

info@caprion.com